Co-Diagnostics, Inc.

For the period ended Sep 30, 2025. Filed Nov 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 13, 2025

CODX$0.29-9.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Stockholders’ Equity

Convertible Preferred Stock · Common Stock · Treasury · Additional Paid-in · Accumulated Other Comprehensive · Accumulated Earnings · Total Stockholders’
Shares · Amount · Shares · Amount · Stock · Capital · Income · (Deficit) · Equity
Balance as of December 31, 2024	-	$	-	37,902,222	$37,902	$(15,575,795)	$102,472,210	$418,443	$(33,040,842)	$54,311,918
Issuance of common stock related to at-the-market offering, net of offering costs	-		-	519,099	519	-	354,227	-	-	354,746
Stock-based compensation	-		-	-	-	-	875,228	-	-	875,228
Other comprehensive loss, net of tax	-		-	-	-	-	-	(87,790)	-	(87,790)
Net loss	-		-	-	-	-	-	-	(7,533,271)	(7,533,271)
Balance as of March 31, 2025	-		-	38,421,321	38,421	(15,575,795)	103,701,665	330,653	(40,574,113)	47,920,831
Issuance of common stock related to at-the-market offering, net of offering costs	-		-	1,375,325	1,375	-	427,625	-	-	429,000
Stock-based compensation	-		-	734,500	735	-	579,530	-	-	580,265
Issuance of common stock related to financial advisory services	-		-	500,000	500	-	134,500	-	-	135,000
Other comprehensive loss, net of tax	-		-	-	-	-	-	(196,585)	-	(196,585)
Net loss	-		-	-	-	-	-	-	(7,730,117)	(7,730,117)
Balance as of June 30, 2025	-		-	41,031,146	41,031	(15,575,795)	104,843,320	134,068	(48,304,230)	41,138,394
Issuance of common stock related to at-the-market offering, net of offering costs	-		-	2,341,114	2,341	-	584,659	-	-	587,000
Stock-based compensation	-		-	-	-	-	500,585	-	-	500,585
Issuance of common stock related to registered direct offering, net of offering costs	-		-	9,619,000	9,619	-	3,518,650	-	-	3,528,269
Other comprehensive income, net of tax	-		-	-	-	-	-	(39,180)	-	(39,180)
Net loss	-		-	-	-	-	-	-	(5,886,823)	(5,886,823)
Balance as of September 30, 2025	-	$	-	52,991,260	$52,991	$(15,575,795)	$109,447,214	$94,888	$(54,191,053)	$39,828,245

Convertible Preferred Stock · Common Stock · Treasury · Additional Paid-in · Accumulated Other Comprehensive · Accumulated Earnings · Total Stockholders’
Shares · Amount · Shares · Amount · Stock · Capital · Income · (Deficit) · Equity
Balance as of December 31, 2023	-	$	-	36,108,346	$36,108	$(15,575,795)	$96,808,436	$146,700	$4,598,166	$86,013,615
Stock-based compensation	-		-	18,750	19	-	1,571,215	-	-	1,571,234
Other comprehensive income, net of tax	-		-	-	-	-	-	79,855	-	79,855
Net loss	-		-	-	-	-	-	-	(9,312,043)	(9,312,043)
Balance as of March 31, 2024	-		-	36,127,096	36,127	(15,575,795)	98,379,651	226,555	(4,713,877)	78,352,661
Stock-based compensation	-		-	632,584	633	-	1,499,025	-	-	1,499,658
Other comprehensive income, net of tax	-		-	-	-	-	-	144,653	-	144,653
Net loss	-		-	-	-	-	-	-	(7,599,318)	(7,599,318)
Balance as of June 30, 2024	-		-	36,759,680	36,760	(15,575,795)	99,878,676	371,208	(12,313,195)	72,397,654
Stock-based compensation	-		-	18,750	18	-	1,045,565	-	-	1,045,583
Other comprehensive income, net of tax	-		-	-	-	-	-	37,158	-	37,158
Net loss	-		-	-	-	-	-	-	(9,696,455)	(9,696,455)
Balance as of September 30, 2024	-	$	-	36,778,430	$36,778	$(15,575,795)	$100,924,241	$408,366	$(22,009,650)	$63,783,940

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.